This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Freenome said Friday it plans to go public in a deal that ...
In early 2022, Freenome surpassed $1 billion in lifetime financing after raking in two nine-figure funding rounds barely a month apart, with plans to use the money to launch new studies of its cancer ...
SAN FRANCISCO—If there’s one silver lining to the COVID-19 pandemic, it’s the amount of rapid innovation that occurred across medtech, biotech and healthcare to better serve patients who had either ...
Freenome published topline results this week from a study of its blood-based test for the early detection of colorectal cancer, though the data fell short of expectations and rival diagnostics. The ...
(Reuters) - Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
SOUTH SAN FRANCISCO, Jan. 24, 2022 /PRNewswire/ -- Freenome, a privately held biotech company, presented at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) symposium last ...
Investors have poured boatloads of cash into liquid biopsy companies promising that their technology is the solution for non-invasive screening of early-stage cancer. In the latest mega funding round, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results